tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2014 Jun 17;10(8). [Epub ahead of print]
Burden of vaccine-preventable disease in adult Medicaid and commercially insured populations: Analysis of claims-based databases, 2006-2010.
Krishnarajah G1, Carroll C2, Priest J2, Arondekar B3, Burstin S1, Levin M4.
Author information
Abstract
Vaccination rates among United States (US) adults are suboptimal, resulting in morbidity, mortality, and financial burden attributable to potentially vaccine-preventable diseases (VPDs). Unadjusted annual incidence proportions of VPDs were estimated for Medicaid and commercially insured adults aged 19-64 years using 2006-2010 claims, along with age/gender-adjusted incidence proportions for 2010. In 2010, 1.6 million Medicaid adults (mean age 34 ? 12 years; 73.4% female) and 33 million commercially insured (mean age 42 ? 13 years; 52.2% female) were included. Age/gender-adjusted incidence proportions (per 100 000) in 2010 among Medicaid vs commercially insured adults for meningococcal disease were 26.2 (95% CI 22.9-29.8) vs 2.0 (1.9-2.2) (P<0.001); hepatitis B 88.9 (82.6-95.6) vs 17.5 (17.0-17.9) (P<0.001); pneumococcal disease 98.2 (91.7-105.1) vs 21.1 (20.7-21.6) (P<0.001); hepatitis A 19.8 (16.9-23.1) vs 4.5 (4.3-4.7) (P<0.001); mumps 2.1 (1.3-3.3) vs 1.4 (1.3-1.6) (P = 0.14); measles 0.3 (0.1-1.0) vs 0.3 (0.2-0.3) (P = 0.38); herpes zoster (60- to 64-year-olds only) 459 (408-515) vs 473 (466-481) (P = 0.35); varicella (19- to 39-year-olds only) 6.5 (4.8-8.5) vs 8.0 (7.5-8.5) (P = 0.12); influenza 586 (573-598) vs 633 (631-636) (P<0.001); and pertussis 1.8 (1.1-2.8) vs 3.2 (3.0-3.4) (P<0.001). Research is needed to fully understand the causes of the disparity of the coded incidence of some VPDs in adult Medicaid population than commercially insured adults in the US.
KEYWORDS:
Medicaid; commercially insured; health disparity; immunization adults; vaccine-preventable diseases
PMID:
24936874
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24936874
Burden of vaccine-preventable disease in adult Medicaid and commercially insured populations: Analysis of claims-based databases, 2006-2010.
Krishnarajah G1, Carroll C2, Priest J2, Arondekar B3, Burstin S1, Levin M4.
Author information
Abstract
Vaccination rates among United States (US) adults are suboptimal, resulting in morbidity, mortality, and financial burden attributable to potentially vaccine-preventable diseases (VPDs). Unadjusted annual incidence proportions of VPDs were estimated for Medicaid and commercially insured adults aged 19-64 years using 2006-2010 claims, along with age/gender-adjusted incidence proportions for 2010. In 2010, 1.6 million Medicaid adults (mean age 34 ? 12 years; 73.4% female) and 33 million commercially insured (mean age 42 ? 13 years; 52.2% female) were included. Age/gender-adjusted incidence proportions (per 100 000) in 2010 among Medicaid vs commercially insured adults for meningococcal disease were 26.2 (95% CI 22.9-29.8) vs 2.0 (1.9-2.2) (P<0.001); hepatitis B 88.9 (82.6-95.6) vs 17.5 (17.0-17.9) (P<0.001); pneumococcal disease 98.2 (91.7-105.1) vs 21.1 (20.7-21.6) (P<0.001); hepatitis A 19.8 (16.9-23.1) vs 4.5 (4.3-4.7) (P<0.001); mumps 2.1 (1.3-3.3) vs 1.4 (1.3-1.6) (P = 0.14); measles 0.3 (0.1-1.0) vs 0.3 (0.2-0.3) (P = 0.38); herpes zoster (60- to 64-year-olds only) 459 (408-515) vs 473 (466-481) (P = 0.35); varicella (19- to 39-year-olds only) 6.5 (4.8-8.5) vs 8.0 (7.5-8.5) (P = 0.12); influenza 586 (573-598) vs 633 (631-636) (P<0.001); and pertussis 1.8 (1.1-2.8) vs 3.2 (3.0-3.4) (P<0.001). Research is needed to fully understand the causes of the disparity of the coded incidence of some VPDs in adult Medicaid population than commercially insured adults in the US.
KEYWORDS:
Medicaid; commercially insured; health disparity; immunization adults; vaccine-preventable diseases
PMID:
24936874
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24936874